BRD4 and colorectal carcinoma: The combination of the BRD4 BET inhibitor JQ1 and WNT or MAPK inhibitors is an effective therapeutic option in CRC, as the combined treatment sufficiently suppresses cell proliferation via the reduction in MYC expression (Figure 2A).